KKR, TPG in Early-Stage Buyout Talks for Relisys Medical Devices

Story ByNikita Saha

•

KKR, TPG in Early-Stage Buyout Talks for Relisys Medical Devices

The potential deal, estimated to be valued between INR 1,200 Cr and INR 1,300 Cr, could see an exit for existing investor Siguler Guff, according to people familiar with the matter.

Global investment firms KKR and TPG are reportedly in preliminary discussions to acquire Hyderabad-based med-tech manufacturer Relisys Medical Devices.

The potential deal, estimated to be valued between INR 1,200 Cr and INR 1,300 Cr, could see an exit for existing investor Siguler Guff, according to people familiar with the matter.

While the negotiations remain at an early stage, with limited details available regarding the specific terms, valuation, and assets involved, sources indicate that a definitive agreement may still be some distance away.There is also the possibility that discussions could be called off.

For KKR, this transaction would complement its growing Healthium MedTech platform in India, while for TPG, it could mark a strategic step in building its med-tech investment portfolio.

Both firms’ interest reflects the increasing private equity appetite in India’s fast-expanding healthcare and medical devices sector, driven by demand for affordable, high-quality surgical and diagnostic solutions.

Founded in 1997 in Rangareddy, Telangana, Relisys Medical Devices has established itself as a leading manufacturer of cardiovascular medical devices. The company offers a range of products, including coronary stent systems (bare metal and drug-eluting stents), PTCA balloon catheters, angiographic diagnostic catheters, guiding catheters, and transcatheter heart valves. It remains the only integrated facility in India with in-house development and manufacturing capabilities for these critical cardiovascular products.

Relisys has actively broadened its product range and market presence through strategic acquisitions, notably Multimedics, which enabled the company to secure CE-marked stent systems and strengthen its global footprint. The firm continues to focus on delivering reliable, affordable, and life-saving medical technologies, with a mission to improve patient outcomes across India and international markets.

As discussions progress, the deal could further intensify investor activity in India’s med-tech landscape, particularly in segments like cardiovascular devices and surgical solutions, where demand is surging amid a growing burden of non-communicable diseases.